Literature DB >> 2511810

The advantages of a gonadotropin releasing hormone agonist (leuprolide acetate) in conjunction with gonadotropins for controlled ovarian hyperstimulation in IVF and GIFT cycles.

J F Kerin1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2511810     DOI： 10.1007/bf00935852

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN： 0932-0067            Impact factor:   2.344


× No keyword cloud information.
  6 in total

1.  Pregnancy: a risk to initiation of leuprolide acetate during the luteal phase before controlled ovarian hyperstimulation.

Authors:  P Serafini; J Batzofin; J Kerin; R Marrs
Journal:  Fertil Steril       Date:  1988-08       Impact factor: 7.329

2.  Short-term use of gonadotropin-releasing hormone agonist (leuprolide) for in vitro fertilization.

Authors:  K P Katayama; M Roesler; C Gunnarson; E Stehlik; S Jagusch
Journal:  J In Vitro Fert Embryo Transf       Date:  1988-12

3.  An alternate approach to controlled ovarian hyperstimulation in "poor responders": pretreatment with a gonadotropin-releasing hormone analog.

Authors:  P Serafini; B Stone; J Kerin; J Batzofin; P Quinn; R P Marrs
Journal:  Fertil Steril       Date:  1988-01       Impact factor: 7.329

4.  Stimulation of LH fragments with reduced bioactivity following GnRH agonist administration in women.

Authors:  D R Meldrum; Z Tsao; S E Monroe; G D Braunstein; J Sladek; J K Lu; W Vale; J Rivier; H L Judd; R J Chang
Journal:  J Clin Endocrinol Metab       Date:  1984-04       Impact factor: 5.958

Review 5.  The neuroendocrine control of the menstrual cycle.

Authors:  E Knobil
Journal:  Recent Prog Horm Res       Date:  1980

6.  Follicular atresia associated with concurrent initiation of gonadotropin-releasing hormone agonist and follicle-stimulating hormone for oocyte recruitment.

Authors:  R G Brzyski; S J Muasher; K Droesch; S Simonetti; G S Jones; Z Rosenwaks
Journal:  Fertil Steril       Date:  1988-12       Impact factor: 7.329
  6 in total
  2 in total

1.  Incomplete androgen and progesterone suppression following midluteal GnRHa prior to controlled ovarian hyperstimulation for IVF-ET.

Authors:  T J Gelety; E S Surrey
Journal:  J Assist Reprod Genet       Date:  1997-10       Impact factor: 3.412

Review 2.  Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders.

Authors:  G L Plosker; R N Brogden
Journal:  Drugs       Date:  1994-12       Impact factor: 9.546
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.